NCT01172067

Brief Summary

The purpose of this study is to demonstrate that QuickOpt optimization can be as an alternative method for CRTP/D patients' optimization in clinical practice through the comparison of the improvement differences between the CRTP/D patients with different optimization at 12 months after implantation.The hypothesis is that the Heart Remolding parameter (LVESV) improvement of patients using QuickOpt parameters at 12 months after implant is not inferior (10%) to the patients by Echo optimization。

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for not_applicable heart-failure

Timeline
Completed

Started May 2010

Longer than P75 for not_applicable heart-failure

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2010

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

July 28, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 29, 2010

Completed
5.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2016

Completed
3.7 years until next milestone

Results Posted

Study results publicly available

September 30, 2019

Completed
Last Updated

October 8, 2019

Status Verified

September 1, 2019

Enrollment Period

5.6 years

First QC Date

July 28, 2010

Results QC Date

May 29, 2019

Last Update Submit

September 27, 2019

Conditions

Keywords

CRTheart failureoptimizationTiming cycle optimization methods

Outcome Measures

Primary Outcomes (1)

  • Percent Change in Left Ventricular End Systolic Volume (LVESV) at 12 Months Compared to Baseline

    The primary outcome is the percent change in LVESV at 12 months compared to baseline. This outcome measure is assessed through evaluation of echocardiograms at both baseline and 12 months, with a decrease in the percent change in LVESV at 12 months indicating clinical improvement. The percent change in patients with devices optimized with QuickOpt is compared with that of patients with devices optimized using standard echocardiography techniques to determine if one method of optimization results in a greater change in LVESV.

    Baseline and12 months

Study Arms (2)

Quickopt Group

EXPERIMENTAL

the QuickOpt Group patients will be optimized by QuickOpt(IEGM);

Device: Cardiac Resynchronization Therapy

Echocardiography group

ACTIVE COMPARATOR

the Echo Group patients will be optimized by Echo.

Device: Optimization using echocardiography

Interventions

Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.

Quickopt Group

Optimization of the AV/PV and VV delays using echocardiography

Echocardiography group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient meets current CRT-P indications and be implanted with an SJM CRT-P device with V-V timing and a compatible lead system
  • Patient is able to provide written informed consent for study participation

You may not qualify if:

  • Patient has limited intrinsic atrial activity (≤ 40 bpm)
  • Patient has persistent or permanent AF
  • Patient has a 2o or 3o heart block
  • Patient's life expectancy is \<12 months
  • Patient is \<18 years old
  • Patient is pregnant
  • Patient is on IV inotropic agents
  • Patients who are ongoing other devices or agents study
  • Patients with heart transplanted or waiting for heart transplant
  • Patients with Hypertrophic and obstructive cardiomyopathy
  • Patients with severe aortic valve and mitral valve stenosis or regurgitation without replacement

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fuwai Hospital

Beijing, Beijing Municipality, 100037, China

Location

MeSH Terms

Conditions

Heart Failure

Interventions

Cardiac Resynchronization Therapy

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Cardiac Pacing, ArtificialElectric Stimulation TherapyTherapeutics

Results Point of Contact

Title
Clay Cohorn, Program Director
Organization
CRT, Global Clinical Affairs, Cardiac Arrhythmias and Heart Failure, Abbott Medical Devices

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 28, 2010

First Posted

July 29, 2010

Study Start

May 1, 2010

Primary Completion

December 1, 2015

Study Completion

January 1, 2016

Last Updated

October 8, 2019

Results First Posted

September 30, 2019

Record last verified: 2019-09

Locations